ArticleProceedings of the National Academy of Sciences of the United States of America2018
Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy.Frontiers in microbiology · 2025Review
- Augmented antitumor immune responses of HER2-targeted pyroptotic induction by long-lasting recombinant immunopyroptotins.Heliyon · 2024Article
- Albumin binding improves nanobody pharmacokinetics for dual-modality PET/NIRF imaging of CEACAM5 in colorectal cancer models.European journal of nuclear medicine and molecular imaging · 2023Article
- Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer.European journal of nuclear medicine and molecular imaging · 2023Article
- Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.Cancer medicine · 2023Article
- CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin.Biomaterials research · 2022Article
- Directing ricin-based immunotoxins with targeting affibodies and KDEL signal peptide to cancer cells effectively induces apoptosis and tumor suppression.Journal of nanobiotechnology · 2022Article
- Extracellular vesicles engineered to bind albumin demonstrate extended circulation time and lymph node accumulation in mouse models.Journal of extracellular vesicles · 2022Article
- Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.Antibody therapeutics · 2022Review
- Intraductal administration of transferrin receptor-targeted immunotoxin clears ductal carcinoma in situ in mouse models of breast cancer-a preclinical study.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling.Molecular cancer therapeutics · 2022Article
- Deciphering albumin-directed drug delivery by imaging.Advanced drug delivery reviews · 2022Review
- Antibody-Based Immunotoxins for Colorectal Cancer Therapy.Biomedicines · 2021Review
- An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine.Frontiers in immunology · 2021Article
- Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation.Biomolecules · 2020Review
- Structure-activity analysis of truncated albumin-binding domains suggests new lead constructs for potential therapeutic delivery.The Journal of biological chemistry · 2020Article
- Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.Biomolecules · 2020Review
- Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update.Biomolecules · 2020Review
- Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.Hepatology (Baltimore, Md.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant immunotoxins (RITs) are chimeric proteins consisting of a Fv that binds to a cancer cell and a portion of a protein toxin. One of these, Moxetumomab pasudotox, was shown to be effective in treating patients with some leukemias, where the cells are readily accessible to the RIT. However, their short half-life limits their efficacy in solid tumors, because penetration into the tumors is slow. Albumin and agents bound to albumin have a long half-life in the circulation. To increase the time tumor cells are exposed to RITs, we have produced and evaluated variants that contain either an albumin-binding domain (ABD) from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.